Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 5/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13250347 | 0.90 | PRLHR (0.45) | PRLHRMGLLHRH3MTHFD2EPHX2 | |
| SCHEMBL13250081 | 0.90 | MGLL (0.39) | PRLHRMGLLUSP2CYP3A4CYP2D6 | |
| SCHEMBL13249859 | 0.89 | USP2 (0.49) | PRLHRMTHFD2USP2CYP3A4CYP2D6 | |
| SCHEMBL13250445 | 0.88 | P2RX7 (0.45) | PRLHRMTHFD2P2RX7 | |
| SCHEMBL13249831 | 0.88 | MTHFD2 (0.46) | MTHFD2P2RX7 | |
| SCHEMBL13249931 | 0.87 | HRH3 (0.44) | PRLHRHRH3EPHX2 | |
| SCHEMBL13250101 | 0.86 | MGLL (0.38) | PRLHRMGLLUSP2CYP3A4CYP2D6 | |
| SCHEMBL14047859 | 0.85 | MTHFD2 (0.45) | PRLHRMTHFD2P2RX7 | |
| SCHEMBL13249858 | 0.85 | PRLHR (0.45) | PRLHRMTHFD2P2RX7 | |
| SCHEMBL13249874 | 0.84 | MTHFD2 (0.43) | PRLHRMTHFD2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | PRLHR 263/4885MGLL 882/4885HRH3 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.